Finance

1inch Announces Fusion+ Upgrade, Enabling Secure, Decentralized Cross-Chain Swaps for Web3 Users

Dubai, UAE, September 18th, 2024, FinanceWire

1inch is thrilled to unveil Fusion+, bringing users cross-chain functionality in an upgrade of the intent-based swap product. With Fusion+, users can retain full self-custody of their assets, while the architecture ensures transactions are fully completed on the two networks involved in the swap, without relying on third parties.

1inch, a decentralized finance (DeFi) project, has introduced Fusion+, an upgrade designed to enhance cross-chain swaps by integrating liquidity from across the Web3 ecosystem. The introduction of 1inch Fusion brings together on- and off-chain liquidity using an intent-based approach to deliver convenient and secure swaps designed with built-in MEV protection.

While historically, cross-chain swaps were hindered by slow, costly bridges and risks of centralized exchanges, Fusion+ aims to address these challenges by offering a decentralized, self-custodial solution that taps into the vast liquidity of Web3, ensuring users get the best rates with unmatched security.

Fusion+ is a true cross-chain gamechanger. This upgrade integrates liquidity from the entire Web3 ecosystem, enabling fast, efficient and secure cross-chain swaps – all from a single platform. The cross-chain swap upgrade builds on the intent-based approach introduced with the launch of 1inch Fusion in late 2022, as well as groundbreaking atomic swap technology.

The 1inch Fusion swaps works as follows: users specify the minimum return they’re willing to accept, and professional traders, known as resolvers, compete to execute swaps at the most favorable rates. The pricing is determined through a Dutch auction model, where Fusion swaps’ filling rates decrease over time, influenced by swap volume and user-established presets, which define price and duration limits. A smart price curve accounts for market liquidity and adjusts based on gas prices to ensure optimal execution for users.

The Benefits of Atomic Swap Technology

Fusion+ integrates atomic swap technology, ensuring that cross-chain swaps are:

  • Secure: “atomic” swaps are designed to be all-or-nothing transactions. If a swap fails to complete for any reason (such as timelock expiration), the assets are safely returned to the original owner.
  • Trustless: both parties can exchange assets without the need for mutual trust, as the swap is governed by smart contracts. These contracts verify all conditions of the transaction, meaning no one needs to trust each other or a third party to make the swap happen.

The key takeaway is that the process is entirely trustless, functioning purely through verification. This critical aspect of verification is also applied in Fusion+ cross-chain swaps, which is why users must keep the Swap tab in the dApp or application (when available in the 1inch Wallet) open until the swap is fully verified, ensuring the highest level of safety.

Currently, Fusion+ is in its beta version, and users who wish to try cross-chain swaps need to manually enable Fusion+ in Settings. After the testing period, Fusion+ cross-chain swaps will be automatically enabled.

Behind the scenes: the mechanics of Fusion+

The process works as follows: For example, a user holds POL tokens on Polygon and wants to swap them for ETH on Ethereum.

  • Initiating the swap: a user enters order details in the swap form, and the order is shared with resolvers. A Dutch auction begins, where the price decreases until a resolver accepts the order.
  • Locking the funds: the resolver deposits the user’s POL tokens into an escrow contract on Polygon by executing the 1inch Fusion order. The escrow contract includes the secret hash, token details and a timelock. Simultaneously, the resolver deposits ETH into an escrow on Ethereum, using the same secret and conditions.
  • Completing the swap: once both contracts are active on-chain, the cryptographic secret is revealed. The resolver unlocks ETH to the user on Ethereum and claims the POL tokens on Polygon, finalizing the exchange.

  • Timelock protection: if the swap is not completed within the designated time, the resolver cancels the contracts, and the funds are returned to their original owners.

Fusion+ now live in the 1inch dApp, coming soon to the 1inch Wallet

Users can experience seamless Fusion+ cross-chain swaps in the 1inch dApp. To be among the first to leverage these benefits, users can enable Fusion+ in Settings. With Fusion+, 1inch is setting a new cross-chain standard while advancing the security and decentralization of the Web3 space.

About 1inch

1inch is a leading DeFi project empowering Web3 users with innovative blockchain products and solutions. Launched in 2019 at a hackathon in New York City, 1inch offers users and developers the most secure, reliable, and efficient tools for growing and expanding the Web3 space.

Currently, 1inch Swap is a top DEX aggregator on the market, facilitating cost-efficient and secure crypto swaps across multiple liquidity sources. The 1inch Wallet is one of the most user-friendly and secure Web3 wallets, and the 1inch Portfolio is highly regarded as one of the most efficient DeFi trackers, providing accurate analytics on the market for numerous DeFi protocols. In line with its active involvement in the community, in 2023, 1inch launched the Developer Portal, offering an extensive suite of Web3 tools and services. For more information, readers can visit https://1inch.io.

Contact

PR lead
Pavel Kruglov
1inch Labs
p.kruglov@1inch.io

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

2024-09-19T13:00:00Z

Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes

AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”

Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”

The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.

Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”

Key contributions from PersonalAIze include:

  • Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
  • Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
  • Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
  • Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
  • Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.

Key Resources and Support from PersonalAIze
As part of the collaboration, PersonalAIze will contribute:

  • Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
  • Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
  • Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
  • Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
  • Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
  • Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
  • Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.

About PersonalAIze
PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.

About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.


GlobeNewsWire News

Recent Comments